Active pharmaceutical ingredients market seen reaching $198.39 billion by 2030

The global active pharmaceutical ingredients (API) market is projected to reach USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a CAGR of 6.6% from 2025 to 2030. Growth is driven by rising demand for both innovative and generic drugs, expanding biopharmaceutical pipelines, and increasing investments in drug development worldwide.

The expansion of the market has been predominantly fueled by the expanding oncology, rare disease, and diabetes product pipeline. Over the past few years, type 2 diabetes and obesity care have been reshaped by peptide-based drugs including Semaglutide, Tirzepatide, Liraglutide, and Dulaglutide, creating significant opportunities across the API supply chain.

By potency, the high potency active pharmaceutical ingredients (HPAPI) segment is expected to witness the highest CAGR during the forecast period. The increasing adoption of targeted therapies, particularly in oncology, is driving demand for HPAPIs, which are essential for advanced treatments such as antibody-drug conjugates (ADCs) and precision medicines.

By synthesis type, the synthetic APIs segment accounted for the largest market share in 2024. This was attributed to advancements in chemical synthesis technologies, cost-effectiveness, and scalability, while biotech APIs are gaining traction in specialized applications.

By type, innovative APIs accounted for the largest market share in 2024, supported by the increasing number of regulatory approvals for new and advanced drugs. The source material said the US FDA approved more than 50 new molecular entities in 2024, while innovative APIs, being protected by patents, are typically priced higher than generic APIs.

Based on end users, the pharmaceutical and biotechnology industry accounted for the largest share in 2024. Companies have increased manufacturing outsourcing to contract manufacturers in the last five years, especially for high-potency drugs, ADCs, and biologics, while retaining in-house manufacturing for high-value blockbuster drugs and biologics.

Regionally, North America held the largest share of the API market in 2024, supported by a well-established pharmaceutical industry, advanced manufacturing infrastructure, and strong regulatory frameworks. The source material also said Asia Pacific is projected to achieve the highest CAGR, driven by cost-efficient manufacturing and rising demand for both innovative and generic APIs.

Challenges cited for the market include high production costs, supply chain disruptions, and stringent regulatory requirements. Key companies named in the source material included Pfizer, Teva Pharmaceutical Industries, Merck KGaA, Divi’s Laboratories, Sandoz Group, SK Inc., Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Cipla, Aurobindo Pharma, BASF, Evonik Industries, and EUROAPI.